Tricyclic antidepressants and the incidence of certain cancers: a study using the GPRD
2011

Tricyclic Antidepressants and Cancer Risk

Sample size: 31953 publication Evidence: moderate

Author Information

Author(s): Walker A J, Card T, Bates T E, Muir K

Primary Institution: University of Nottingham

Hypothesis

Tricyclic antidepressants may have a protective effect against glioma and colorectal cancer.

Conclusion

Tricyclic antidepressants may help reduce the risk of colorectal cancer and glioma.

Supporting Evidence

  • Statistically significant reduction in tricyclic prescriptions in glioma and colorectal cancer patients compared to controls.
  • The effects were dose-dependent and time-dependent.
  • No significant association was found for lung, breast, and prostate cancers.

Takeaway

This study found that taking certain antidepressants might help prevent some types of cancer, like brain and colon cancer.

Methodology

A case-control study using the General Practice Research Database to examine the association between tricyclic antidepressant use and cancer incidence.

Potential Biases

Confounding by indication, particularly with SSRIs and depression.

Limitations

Potential for residual confounding due to missing data on smoking, obesity, and alcohol use.

Participant Demographics

Median age of participants was 68.2 years, with 50.7% females.

Statistical Information

P-Value

0.0005 for glioma, 0.001 for colorectal cancer

Confidence Interval

Glioma: 0.42–0.81, Colorectal: 0.75–0.94

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1038/sj.bjc.6605996

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication